Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials

Am J Ther. 2024 Sep-Oct;31(5):e619-e622. doi: 10.1097/MJT.0000000000001756.

Authors

Hazem Ayesh¹, Suhail Ayesh², Kevin Niswender¹

Affiliations

¹ Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, TN.
² Gene Medical Labs, Gaza, Palestine.

PMID: 39292847
DOI: 10.1097/MJT.0000000000001756

No abstract available

Publication types

Comparative Study
Letter
Meta-Analysis

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor Agonists / administration & dosage
Glucagon-Like Peptide-1 Receptor Agonists / adverse effects
Glucagon-Like Peptides* / analogs & derivatives
Humans
Immunoglobulin Fc Fragments* / administration & dosage
Immunoglobulin Fc Fragments* / adverse effects
Obesity / drug therapy
Randomized Controlled Trials as Topic
Recombinant Fusion Proteins* / administration & dosage
Recombinant Fusion Proteins* / adverse effects
Treatment Outcome
Weight Loss* / drug effects

Substances

dulaglutide
Glucagon-Like Peptides
Immunoglobulin Fc Fragments
Recombinant Fusion Proteins
mazdutide
Glucagon-Like Peptide-1 Receptor Agonists